Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Variation in CYP2A6 Activity and Personalized Medicine.

Tanner JA, Tyndale RF.

J Pers Med. 2017 Dec 1;7(4). pii: E18. doi: 10.3390/jpm7040018. Review.

2.

Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

López-Flores LA, Pérez-Rubio G, Falfán-Valencia R.

EXCLI J. 2017 Mar 6;16:174-196. doi: 10.17179/excli2016-847. eCollection 2017. Review.

3.

Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Tanner JA, Henderson JA, Buchwald D, Howard BV, Nez Henderson P, Tyndale RF.

Pharmacogenet Genomics. 2017 May;27(5):169-178. doi: 10.1097/FPC.0000000000000271.

PMID:
28181923
4.

Genetic determinants of CYP2A6 activity across racial/ethnic groups with different risks of lung cancer and effect on their smoking intensity.

Park SL, Tiirikainen MI, Patel YM, Wilkens LR, Stram DO, Le Marchand L, Murphy SE.

Carcinogenesis. 2016 Mar;37(3):269-279. doi: 10.1093/carcin/bgw012. Epub 2016 Jan 27.

5.

CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Wassenaar CA, Zhou Q, Tyndale RF.

Pharmacogenomics. 2016;17(2):147-62. doi: 10.2217/pgs.15.156. Epub 2015 Dec 15.

6.

Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.

Yang L, Yang Y, Qin Q, Zhou A, Zhao J, Wang J, Shu C, Yuan X, Hu S.

Mol Clin Oncol. 2014 Jan;2(1):93-98. Epub 2013 Sep 23.

7.

Association of CYP2A6*4 with susceptibility of lung cancer: a meta-analysis.

Wang L, Zang W, Liu J, Xie D, Ji W, Pan Y, Li Z, Shen J, Shi Y.

PLoS One. 2013 Apr 9;8(4):e59556. doi: 10.1371/journal.pone.0059556. Print 2013. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/1e88e5e7-a6f9-426b-b9c5-26fc923a23c2. Retraction in: PLoS One. 2016;11(7):e0160299.

8.

The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.

Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):708-18. doi: 10.1158/1055-9965.EPI-12-1234-T. Epub 2013 Jan 31.

9.

Nicotine intake and smoking topography in smokers with bipolar disorder.

Williams JM, Gandhi KK, Lu SE, Steinberg ML, Benowitz NL.

Bipolar Disord. 2012 Sep;14(6):618-27. doi: 10.1111/j.1399-5618.2012.01047.x.

10.

PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

McDonagh EM, Wassenaar C, David SP, Tyndale RF, Altman RB, Whirl-Carrillo M, Klein TE.

Pharmacogenet Genomics. 2012 Sep;22(9):695-708. doi: 10.1097/FPC.0b013e3283540217. Review. No abstract available.

11.

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.

Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Rhee J, Park YI, Kim NK.

Br J Cancer. 2011 Mar 29;104(7):1126-34. doi: 10.1038/bjc.2011.24. Epub 2011 Mar 1.

12.

Associations of CYP2A6 genotype with smoking behaviors in southern China.

Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, He YH, Yu XQ, Chen W, Crump C, Wen XZ, Chen WQ.

Addiction. 2011 May;106(5):985-94. doi: 10.1111/j.1360-0443.2010.03353.x.

13.

A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.

Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF.

Pharmacogenomics J. 2009 Aug;9(4):274-82. doi: 10.1038/tpj.2009.11. Epub 2009 Apr 14.

14.

Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent.

Mwenifumbo JC, Sellers EM, Tyndale RF.

Nicotine Tob Res. 2008 Aug;10(8):1319-25. doi: 10.1080/14622200802238894.

15.

Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.

Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, Krasnow RE, Swan GE, Benowitz NL, Tyndale RF.

Clin Pharmacol Ther. 2008 Jan;83(1):115-21. Epub 2007 May 23.

16.

Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Lee AM, Miksys S, Tyndale RF.

Br J Pharmacol. 2006 Jul;148(6):786-94. Epub 2006 Jun 5.

Supplemental Content

Support Center